Immune co-signaling to treat cancer Book Section
| Authors: | Callahan, M. K.; Wolchok, J. D.; Allison, J. P.; Sharma, P. |
| Editor: | Curiel, T. J. |
| Article/Chapter Title: | Immune co-signaling to treat cancer |
| Abstract: | The past two decades have been marked by a growing understanding of the co-stimulatory and co-inhibitory pathways that are critical to the generation of an effective, well-regulated immune response. Capitalizing on an increasingly nuanced appreciation for the role that these molecules play in anti-tumor immune responses, a diversity of novel therapies to treat human cancers are being explored. The ground-breaking success of anti-CTLA-4 therapy in the treatment of advanced melanoma has set the stage for the clinical development of agents targeting a diversity of co-stimulatory and co-inhibitory molecules. Herein, we review the co-signaling molecules that regulate T cell activation with a focus on their potential role(s) in anti-tumor immune responses. Where available, pre-clinical and clinical studies evaluating the anti-tumor activity of agents targeting these molecules are presented. © 2013 Springer Science+Business Media New York. All rights are reserved. |
| Book Title: | Cancer Immunotherapy: Paradigms, Practice and Promise |
| ISBN: | 978-1-4614-4731-3 |
| Publisher: | Springer |
| Publication Place: | New York, NY |
| Date Published: | 2013-01-01 |
| Start Page: | 211 |
| End Page: | 280 |
| Language: | English |
| DOI: | 10.1007/978-1-4614-4732-0_8 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 8 -- Export Date: 7 January 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work